Pharmacokinetic Consequences of Pegylation

REFERENCES

• Abuchowski A., Kazo G. M., Verhoest C. R., et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of poly ethylene glycol-asparaginase. Cancer Biochem. Biophys. 1984; 7: 175–186, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Aguayo A., Cortes J., Thomas D., et al. Combination therapy with methotrexate, vincristin, polyethylene glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999; 86: 1202–1209, [CSA], [CROSSREF]
   Google Scholar
• Alberts D. S., Garcia D. J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54: 30–35, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Algranati N. E., Sy S., Modi M. A branched methoxy 40 kDa poly ethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of PEG-interferon α 2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999; 40(suppl.)190A, [CSA]
   Google Scholar
• Allemann E., Gravel P., Leroux J. C., et al. Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J. Biomed. Mater. Res. 1997; 37: 229–234, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bailon P., Spence C., Schaffer C. A., et al (1999) Pharmacological properties of five polyethylene glycol conjugates of interferon-α -2a. International Conference on Therapies for Viral Hepatitis, Maui, Hawaii, Dec., 61999
   Google Scholar
• Bailon P., Palleroni A., Schaffer C. A., et al. Rationale design of a potent, long lasting form of interferon: A 40 kDa branched poly ethylene glycol-conjugated interferon α -2a for the treatment of hepatitis C. Bioconjug. Chem. 2001; 12: 195–202, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg I. A. J. M., Kate M. T. T., Guo L., et al. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aerations infection. Antimicrob. Agents Chemother. 2002; 46: 2575–2581, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bazile D. V., Ropert C., Huve P. V., et al. Body distribution of fully biodegradable [14 C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992; 13: 1093–1102, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bazile D., Prud'homme C., Bassoullet M. T., et al. Stealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995; 84: 493–498, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Beauchamp C. O., Gonias S. L., Menapace D. P., et al. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alfa 2-macroglobulin. Anal. Biochem. 1983; 131: 25–33, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bedeschi A., Candiani I., Geroni C., Capolongo L. Water soluble camptothecin derivatives. Drugs Future 1997; 22: 1259–1266, [CSA]
   Google Scholar
• Bonora G. M., Ivanova E., Zarytova V., et al. Synthesis and characterization of high molecular mass polyethylene glycol-conjugated oligonucleotides. Bioconjugate Chem. 1997; 8: 793–797, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brenner and Rector's: the Kidney, 5th ed., B. Brenner, F. Rector, Jr. W.B. Saunders Company, Philadelphia 1996
   Google Scholar
• Brigger I., Chaminade P., Marsaud V., et al. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int. J. Pharm. 2001; 214: 37–42, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bucke W. E., Leitzke S., Diederichs J. E., et al. Surface-modified amikacin liposomes: organ distribution and interaction with plasma proteins. J. Drug Target. 1998; 5: 99–108, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bukowski R. M., Tendler C., Cutler D., et al. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002; 95: 389–396, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bullock J., Chowdhury S., Johnston D. Characterization of poly (ethylene glycol) –modified super oxide dismutase: comparison of capillary electrophoresis and matrix assisted laser desorption /ionization mass spectroscopy. Anal. Chem. 1996; 68: 3258–3264, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Burcovich B., Verones F. M., Zarytova V., Bonora G. M. Branched polyethylene glycol(bPEG) conjugated antisense oligonucleotides. Nuleos. Nuleot. 1998; 17: 1567–1570, [CSA]
   Web of Science ®Google Scholar
• Burnham N. L. Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 1994; 51: 210–218, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Calvo P., Gouritin B., Brigger I., et al. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neuros. Methods 2001; 111: 151–155, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Calvo P., Gouritin B., Chacun H., et al. Long circulating PEGylated polycyanoacrylate nanoparticles as new drug carriers for brain delivery. Pharm. Res. 2001; 18: 1157–1166, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chandy T., Rao G. H., Wilson R. F., Das G. S. Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Drug Deliv. 2002; 9: 87–96, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chatelut E., Rostaing L., Gregoire N., et al. A pharmacokinetic model for alpha interferon administered subcutaneously. Br. J. Clin. Pharmacol. 1999; 47: 365–371, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cheng T.-L., Chen B.-M., Chern J.-W., et al. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjugate Chem. 2000; 11: 258–266, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chirila T. V., Rakoczy P. E., Garrett K. L., et al. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 2002; 23: 321–342, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Collen D., Sinnaeve P., Demarsin E., et al. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single bolus treatment of acute myocardial infarction. Cancer 2000; 102: 1766–1772, [CSA]
   Google Scholar
• Conover C. D., Greenwald R. B., Pendri A., et al. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 1998; 42: 407–414, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Conover C. D., Greenwald R. B., Pendri A., Shum K. L. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-Cancer Drug Design 1999; 14: 499–506, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Conover C. D., Pendri A., Lee C., et al. Camptothecin delivery systems: the antitumor activity of a camptothecin 20-O-polyethylene glycol ester transport form. Anti Cancer Res. 1997; 17: 3361–3368, [CSA]
   PubMed Web of Science ®Google Scholar
• Couvreur P., Aubry J. Monoclonal antibodies for the targeting of drugs: application to nanoparticles. Topics in Pharmaceutical Sciences, D. D. Breimer, P. Speises. Elsevier Sciences Publishers B.V., Amsterdam 1983; 305–316
   Google Scholar
• Davis F. F., Abuchowski A., Van Es T., et al. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng. 1978; 4: 169–173, [CSA]
   Google Scholar
• Diwan M., Park T. G. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J. Control. Rel. 2001; 73: 233–244, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dosio F., Arpicco S., Brusa P., et al. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization, and pharmacokinetics. J. Control. Rel. 2001; 46: 107–117, [CSA], [CROSSREF]
   Google Scholar
• Edwards C. K. Pegylated recombinant human soluble tumor necrosis factor receptor type (rHu-STNF-RI): a novel high affinity TNF receptor designed for chronic inflammatory disease. Ann. Rheum. Dis. 1999; 58: I73–I81, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Eliason J. F. Pegylated cytokines-potential application in immunotherapy of cancer. Biodrugs 2001; 15: 705–711, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Esslinger H. V., Haas S., Maurer R., et al. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers. Thromb. Haemost. 1997; 77: 911–919, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hoffmann-La F. Roche, Ltd., data on file
   Google Scholar
• Francis G. E., Fisher D., Delgado C., et al. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques. Int. J. Hematol. 1998; 68: 1–18, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fresta M., Fontana G., Bucolo C., et al. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J. Pharm. Sci. 2001; 90: 288–297, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fujita T., Nishikawa M., Ohtsubo Y., et al. Control of in vivo fate of albumin derivatives utilizing combined chemical modification. J. Drug Target. 1994; 2: 157–165, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gabizon A., Chemla M., Tzemach D., et al. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J. Drug Target. 1996; 3: 391–398, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gabizon A., Martin F. Polyethylene glycol-coated liposomal doxorubicin: rationale for use in solid tumors. Drugs 1997; 54: 15–21, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Garman J., Kalindjian S. B. The preparation and properties of novel reversible polymer-protein conjugates. 2-methoxy polyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators. FEBS Lett. 1987; 223–361, [CSA]
   Google Scholar
• Gbadamosi J. K., Hunter A. C., Moghimi S. M. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett 2002; 532: 338–344, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chognot D., Six J. L., Leonard M., et al. Physicochemical evaluation of PLA nanoparticles stabilized by water-soluble MPEO-PLA block copolymers. J. Colloid Interface Sci. 2003; 268: 441–447, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Glue P., Fang J., Sabo R., et al. A dose ranging study of PEG-Intron and ribavirin in chronic hepatitis C-safety, efficacy, and virological rational. Hepatology 1999a; 30: 303A, [CSA]
   Web of Science ®Google Scholar
• Glue P., Rouzier-panis R., Raffanel C., et al. PEG-interferon-α 2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatology 1999b; 30: 189AA, [CSA]
   Google Scholar
• Grace M., Youngster S., Gitlin G., et al. Structural and biologic characterization of pegylated recombinant IFN-α -2b. J. IFN Cytokine Res. 2001; 21: 1103–1115, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Greenwald R. B., Pendri A., Bolikal D. Highly water soluble taxol derivatives. 7-polyethylene glycol carbamates and carbonates. J. Org. Chem. 1995; 60: 331–336, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Greenwald R. B., Gilbert C. W., Pendri A., et al. Drug delivery systems: water soluble taxol 2-poly (ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 1996a; 39: 424–431, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Greenwald R. B., Pendri A., Conover C., et al. Drug delivery systems: 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J. Med. Chem. 1996b; 39: 1938–1940, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Greenwald R. B., Pendri A., Conover C. V., et al. Camptothecin-20-PEG ester transport forms: the effect of space groups on antitumor activity. Bioorg. Med. Chem. 1998; 6: 551–562, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Greenwald R. B., Conover C. V., Pendri A., et al. Drug delivery of anticancer agents: water soluble 4-poly(ethylene glycol) derivatives of the lignan, podophylotoxin. J. Control. Rel. 1999; 61: 281–294, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gref R., Minamitake Y., Peracchia M. T., et al. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600–1603, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gref R., Domb A., Quellec P., et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug. Deliv. Rev. 1995; 16: 215–233, [CSA]
   PubMed Web of Science ®Google Scholar
• Gref R., Lück M., Quellec P., et al. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surfaces B: Biointerfaces 2000; 18: 301–313, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gupta S. K., Pittance A. L., Swan S. K., et al. Single dose pharmacokinetics and safety of pegylated interferon alfa-2b in patients with chronic renal dysfunction. J. Clin. Pharamacol. 2002; 42: 1109–1115, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Harris J. M., Martin N. E., Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001; 40: 539–551, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Poly(ethylene glycol): Chemistry, and Biomedical Applications, J. M. Harris, S. Zalipsky. ACS Books, Washington, DC 1997
   Google Scholar
• He X. H., Shaw P. C., Tam S. C. Reducing the immunogenicity and improving the in vivo activity of trichosantin by site directed pegylation. Life Sci. 1995; 65: 355–368, [CSA], [CROSSREF]
   Google Scholar
• Heathcof E. J., Shiffman M. L., Cooksley G., et al. Multinational evaluation of the efficacy and safety of once weekly PEG-interferon α -2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensation cirrhosis. Hepatology 1999; 30(suppl.)316A, [CSA]
   PubMedGoogle Scholar
• Hershfield M. S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 1995; 76: S228–S232, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hershfield M. S. Biochemistry and poly (ethylene glycol)–modified adenosine deaminase (PEG-ADA). Poly (ethylene glycol): Chemistry and Biological Applications, J. M. Harris, S. Zolipsky. ACS Books, Washington, DC 1997; 134–144
   Google Scholar
• Hershfield M. S., Chaffee S., Koro-jonson L., et al. Use of site directed mutagenesis to enhance the epitope shielding effect of covalent modification of protein with poly ethylene glycol. Proc. Natl. Acad. Sci. USA 1991; 88: 7185–7189, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hokom M. M., Lacey D., Kinsler O., et al. Megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486–4892, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Holle L. M. Pegaspargase: alternative?. Ann. Pharmacother. 1997; 31: 616–624, 655–656[INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Holmes F. A., O'Shaughnessy J. A., Vukelja S., et al. Blinded, randomized, multicentre study to evaluate single administration PEG filgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 2002; 20: 727–731, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hurwitz E., Klapper L. N., Wilchek M. Y., et al. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunol. Immunother. 2000; 49: 226–234, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Illum L., Jones P. D. E., Kreuter J., et al. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro. Int. J. Pharm. 1983; 17: 65–76, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Illum L., Jones P. D., Baldwin R. W., Davis S. S. Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J. Pharmacol. Exp. Ther. 1984; 230: 733–736, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Illum L., Church A. E., Butterworth M. D., et al. Development of systems for targeting the regional lymph nodes for diagnostic imaging. Pharm Res. 2001; 18: 640–645, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Imaz I. A. New formulation of interferon in treatment of hepatitis: peg-interferon alfa-2b (pegintron). Farm. Hosp. Spain 2002; 133: 9–10, 12–15, CP1[CSA]
   Google Scholar
• Ishida O., Maruyama K., Tanahashi H., et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors. Pharm. Res. 2001; 18: 1042–1048, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Iwanaga K., Ono S., Narioka K., et al. Oral delivery of insulin by using surface coating liposomes: improvement of stability of insulin in GI tract. Int. J. Pharm. 1997; 157: 73–80, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Jaschke A., Furste J. P., Nordhoff E., et al. Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. Nuleic Acids Res. 1994; 22: 4810–4817, [CSA]
   PubMed Web of Science ®Google Scholar
• Jaschke A., Furste J. P., Cech D., Erdmann V. A. Automated incorporation of polyethylene glycol into synthetic oligonuleotides. Tetrahedron Lett. 1993; 34: 301–304, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Katre N. V. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhancing their therapeutic potential. Adv. Drug Del. Rev. 1993; 10: 91–114, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Kawaguchi T., Asakawa H., Tashiro T., et al. Atachability, binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5′-terminal with poly(ethylene glycol). Biol. Pharm. Bull. 1995; 18: 474–576, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kim T. H., Lee H., Park T. G. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 2002; 23: 2311–2317, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kinstler O. B., Brems D. N., Lauren S. L., et al. Characterization and stability of N- terminally PEGylated rhG-CSF. Pharm. Res. 1996; 13: 996–1002, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Knauf M. J., Bell D. P., Hirtzer P., et al. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 1988; 263: 15064–15070, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Koumenis I. L., Shahrokh Z., Leong S., et al. Modulating pharmacokinetics of an anti-interleukin-8 F(ab')2 by amine specific PEGylation with preserved bioactivity. Int. J. Pharm. 2000; 198: 83–95, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kozlowski A., Harris J. M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Rel. 2001; 72: 217–224, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kubiak C., Manil L., Couvreur P. Sorptive properties of antibodies onto cyanoacrylic nanoparticles. Int J Pharm 1988; 41: 181–187, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Laverman P., Dams E. Th. M., Storm G., et al. Microscopic localization of PEG-liposomes in a rat model of focal infection. J. Control. Rel. 2001; 75: 347–355, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lee K. C., Tak K. K., Park M. O., et al. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. Pharm. Dev. Tech. 1999; 4: 269–275, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lee L. S., Conover C., Shi C., et al. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug. Chem. 1999; 10: 973–981, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Levchenko T. S., Rammohan R., Lukyanov A. N., et al. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm. 2002; 240: 95–102, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Li S., Yang Z., Sun X., et al. Protein carboxyl amidation increases the potential extent of protein poly ethylene glycol conjugation. Anal. Biochem. 2004; 330: 204–271, [CSA], [CROSSREF]
   Google Scholar
• Li Y., Pei Y., Zhang X., et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Rel. 2001; 71: 203–211, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lusting R., Byhardt R., Diab S., et al. A clinical phase IB study of PEG-hemoglobin in patients receiving palliative fractioned radiation for solid tumors. J. Clin. Oncol. 1999; 17: 1750, [CSA]
   Google Scholar
• Manil L., Roblot-Treupel L., Couvreur P. Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. Biomaterials 1986; 7: 212–216, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Martinez A., Pendri A., Greenwald R. B. Branched poly(ethylene glycol) linkers. Macromol. Chem. Phys. 1997; 198: 2489–2498, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Maruyama K., Ishida O., Takizawa T., Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev. 1999; 40: 89–102, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Medina J., Garcia Buey L., Moreno Monteagudo J. A., et al. Therapeutic advantages of pegylation of interferon alpha in chronic hepatitis C. Rev. Esp. Enferm. Dig. 2003; 95: 561–574, [CSA]
   Google Scholar
• Moghimi S. M., Hunter A. C., Murray J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001; 53: 283–318, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Moghimi S. M. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta. 2002; 1590: 131–139, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003; 14: 259–264, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Monfardini C., Schiavon O., Caliceti P., et al. A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjug. Chem. 1995; 6: 62–69, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Morstyn G., Foote M., Walker T., Molineux G. Filgrastim(r-metHuG-CSF) in the 21st century: SD/01. Acta Haematol. 2001; 105: 151–155, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mosqueira V. C., Legrand P., Gulik A., et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 2001; 22: 2967–2979, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Murakami Y., Tabata Y., Ikada Y. Tumor accumulation of poly(ethylene glycol) with different with molecular weights after i.v. injection. Drug Del. 1997; 4: 23–32, [CSA]
   Web of Science ®Google Scholar
• Nieforth K. A., Nadeau R., Patel I. H., et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin. Pharmacol. Ther. 1996; 59: 636–646, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Noguchi Y., Wan J., Duncan R., et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jap. J. Cancer 1998; 89: 397–416, [CSA]
   PubMedGoogle Scholar
• Novakova K., Laznicek M., Rypacek F., Machova L. Pharmacokinetics and distribution 125 I-PLA-b-PEO block copolymers in rats. Pharm. Dev. Technol. 2003; 8: 153–161, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nucci M. L., Shorr R. G., Abuchowski A. PEG-Hemoglobin. Drug. Future 1996; 21: 29–32, [CSA]
   Google Scholar
• O'Brien C., Pockros P., Reddy R., et al (1999) A double-blind, multicentre, randomized, parallel dose-comparison study of six regimens of 5KDa, linear peginterferon α -2a compared with roferon-ain patients with chronic hepatitis C. International Conference on Therapies for Viral Hepatitis, Maui, Hawaii, December, 61999
   Google Scholar
• Ochoa L., Tolcher A. W., Rizzo J., et al. A phase I study of PEG-camptothecin(PEG-CPT) in patients with advanced solid tumors: a novel formulation for an insoluble but active agent. J. Clin. Oncol. 2000; 19: 198a, [CSA]
   Google Scholar
• Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 2003; 55: 403–419, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pardridge W. M., Wu D., Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimized brain uptake of brain derived neurotrophic factor following intravenous administration. Pharm. Res. 1998; 15: 576–582, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pedder S. C. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis. 2003; 23: 19–22, suppl. 1[INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pendri C., Conover C. D., Greenwald R. B. Antitumor activity of paclitaxel -2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anti-Cancer Drug Design 1998; 13: 387–395, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Peracchia M. T., Fattal E., Desmaele D., et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Rel. 1999; 60: 121–128, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rajagopalan S., Gonias S. L., Pizzo S. V. A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. J. Clin. Invest. 1985; 75: 413–419, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Reddy K. R. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 2000; 34: 915–923, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Riley T., Govender T., Stolnik S., et al. Colloidal stability and drug incorporation aspects of micellar-like PLA-PEG nanoparticles. Colloids Surfaces B: Biointerfaces 1999; 16: 147–159, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Roberts M. J., Bentley M. D., Harris J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Del. Rev. 2002; 54: 459–476, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sahli H., Tapon-Bretaudiere J., Fischer A. M., et al. Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. Biomaterials 1997; 18: 281–288, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seelig B., Jasche A. Site specific modification of enzymatically synthesized RNA: transcription initiation and Diels Alder reaction. Tetrahedran Lett. 1997; 38: 7729–7732, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Sharp M., Easthope S. E., Keating G. M., Lamb H. M. Polyethylene glycol-liposomal doxorubicin. Drugs 2002; 62: 2089–2126, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shiffman M., Pockros P. J., Reddy R. K., et al. A controlled, randomized, multicentre, ascending dose phase II trial of pegylated interferon α -2a(PEG) vs. standard interferon α -2a(IFNα) for treatment of chronic hepatitis C. Gastroenterology 1999; 116: 1275, [CSA]
   Google Scholar
• Somack R., Saifer M. G., Williams L. D. Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol(41,000-72,000 daltons). Free Radic. Res. Commun. 1991; 12–13: 553–562, [CSA]
   PubMedGoogle Scholar
• Stolnik S., Dunn S. E., Garnett M. C., et al. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 1994; 11: 1800–1808, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sulkowski M., Reindollar R., Yu J. Combination therapy with peginterferon α -2a(PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C(CHC): a phase II open-label study. Hepatology 1999; 30: 197A, [CSA]
   Web of Science ®Google Scholar
• Sun X., Yang Z., Li S., et al. In vitro efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol and pyridoxal 5′ phosphate supplementation. Cancer Res. 2003; 63: 8377–8383, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Trainer P. J., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 2000; 342: 1171–1177, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y., Kihira T., Tsunoda S., et al. Molecular design of hybrid tumour necrosis factor alfa with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer 1995; 71: 963–968, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y., Tsunoda S., Kamada H., et al. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb. Haemost. 1997; 77: 168–173, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Verrecchia T., Spenlehauer G., Bazile D. V., et al. Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J. Control. Rel. 1995; 36: 49–61, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Vorobjev P. E., Zarytova V. F., Bonora G. M. Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNAse H. Nucleos. Nucleot. 1999; 18: 2745–2750, [CSA]
   PubMed Web of Science ®Google Scholar
• Wang Y., Youngster S., Bausch J., et al. Identification of major positional isomers of pegylated IFNalfa-2b. Biochemistry 2000; 39: 10634–10040, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wills R. J., Dennis S., Speigel H. E., et al. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin. Pharmacol. Ther. 1984; 35: 722–727, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Woghiren C., Sharma B., Stein S. Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification. Bioconjug. Chem. 1993; 3: 314, [CSA], [CROSSREF]
   Google Scholar
• Xu Z-X., Patel I., Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEG-IFN) and interferon α -2a (IFN α -2a) to healthy subjects [abstract]. Hepatology 1998; 702, 28 Suppl.[CSA]
   Google Scholar
• Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 1994; 83: 601–606, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yang J. C., Topalian S. L., Schwartzentruber D. J., et al. The use of polyethylene glycol modified interleukin-2(PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 1995; 76: 687–694, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yoo S. D., Jun H., Shin B. S., et al. Pharmacokinetic deposition of polyethylene glycol modified salmon calcitonins in rats. Chem. Pharm. Bull. 2000; 48: 1921–1924, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yuan F., Leuning M., Huang S. K., et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994; 54: 3352–3356, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 1995; 16: 157–182, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Zalipsky S., Gilon C., Zilkha A. Attachment of drugs to polyethylene glycols. Eur. Polym. J. 1985; 19: 1177–1183, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Zalipsky S., Lee C. Use of functionalized poly(ethylene glycol)s for modification of polypeptides. Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications, J. M. Harris. Plenum Press, New York 1992; 347–370
   Google Scholar
• Zambaux M. F., Faivre-Fiorina B., Bonneau F., et al. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials 2000; 21: 975–980, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zeuzem S., Feinman S. V., Rasenack J., et al (2000) Evaluation of the safety and efficacy of once-weekly peginterfron α-2a (PEGASYS™) for chronic hepatitis C: a multinational randomized study. The European Association for the Study of the Liver. Rotterdamthe Netherlands, May, 1-42000
   Google Scholar
• Zeuzem S., Heathcote J. E., Martin N., et al. PegIFN alfa-2a(40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin. Investig. Drugs 2001; 10: 2201–2213, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhao H., Lee C., Sai P., et al. 20-O-acylcamptothecin derivatives: evidence for lacton stabilization. J. Org. Chem. 2000; 65: 4601–4606, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhao X., Harris J. M. Novel degradable poly(ethylene glycol) esters for drug delivery. Poly (ethylene glycol): Chemistry and Biological Applications, J. M. Harris, S. Zolipsky. ACS Books, Washington, DC 1997; 458–482
   Google Scholar